FOLH1 and prostate carcinoma: After enriching CTCs in the peripheral blood of patients with early intermediate and high-risk prostate cancer and patients with metastatic prostate cancer, two CTC-related markers [PSA and prostate specific membrane antigen (PSMA)] were quantified using qPCR and RNA in situ hybridization (ISH).